glp-1 cardiovascular outcomes 2025 news Agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH Beyond Blood Sugar: A Scoping

doi: 10.2337/dc16-0691 58 DejgaardTFFrandsenCSHansenTSAlmdalTUrhammerSPedersen-BjergaardUet al

As of this week, you have your choice of two: Wegovy (semaglutide) or Foundayo (orforglipron)

Be Patient With the Process Results often become more noticeable after the first month of steady dosing

GIP Receptor Agonism (Glucose-dependent Insulinotropic Polypeptide) GIP is an incretin hormone released from the gut in response to food intake

The commercial then calls out the drug industry for not making effective weight loss medications affordable for patients while promoting Hims treatments as lower-cost alternatives to pricey brand-name GLP-1s